Teva's Nuvigil flunks depression study; Biomarin plots study on Batten disease treatment;

 @FierceBiotech: Allergan bags migraine drug in $1B MAP Pharma buyout. More | Follow @FierceBiotech

@JohnCFierce: Hugin's bold promises on future Celgene revenue face first test with Abraxane pancreatic cancer OS data. News  | Follow @JohnCFierce

@RyanMFierce: I'm thinking, at best, Jimenez and Reinhardt are frienemies. Should be interesting to see how this pharma marriage goes. | Follow @RyanMFierce

> Teva Pharmaceuticals ($TEVA) says that Nuvigil (the narcolepsy drug armodafinil) failed a Phase III trial for major depression associated with bipolar disease. An earlier study proved promising and Teva vows to finish its third and final study later this year. Developers routinely plan multiple trials of new depression drugs, which are frequently torpedoed by high placebo responses. Release

> The San Francisco Business Times reports on Biomarin's ($BMRN) plans to launch an early study of a new drug for Batten disease. An INDA is expected soon. Report

> Lupin won FDA approval of an oral generic contraceptive. Report

Medical Device News

 @FierceMedDev: Quest posts 24% Q4 profit drop amid restructuring. More | Follow @FierceMedDev

 @DamianFierce: $JNJ knew about hip implant failure concerns two years before recalling the all-metal devices. News | Follow @DamianFierce

> Abbott faces slumping stent sales in drug-free future. Report

> After FDA ban, Hospira creeps back into the infusion game with Q Core deal. Story

Pharma News

@FiercePharma: Which pharma brands do docs trust most? Advair (GSK), Humira (AbbVie), Enbrel (Amgen/Pfizer) among them, says survey. More | Follow @FiercePharma

 @AlisonBFierce: How Protein Sciences uses cells from the ovaries of armyworms to make the active ingredient in Flublok. Story | Follow @AlisonBFierce

> Clot-fighter Eliquis wins speedy new backing from NICE. News

> Novartis ($NVS) brings ex-COO home to replace Vasella as chairman. Report

Drug Delivery News

> Amunix hooks Janssen with its XTEN delivery technology. Story

> Study: Biotronik's dissolving stent deemed safe, falls short of Abbott's Absorb. Article

> Phosphagenics oxymorphone pain patch close to clinic. Report

> Nanosphere foam delivers drugs to the bladder. News

Biomarkers News

> Researcher spotlights new biomarker for gliomas. Item

> U.K.-based International Diagnostics Centre brings global diagnostics R&D together. Story

> Bill Gates helps genomic tests startup lay firm foundation. Report

> Onconova teams with GVK Biosciences to take cancer biomarkers to IND phase. News

And Finally… An NIH task force believes that most of the government's 700 chimps involved in medical research should be retired as they offer little real advantage in finding or testing new therapies. Story

 

 

Suggested Articles

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.

While screening Caenorhabditis elegans for genetic clues to the PI3K/Akt signaling pathway, scientists found a key protein for insulin synthesis.